Nkarta reported a net loss of $21.7 million for the third quarter of 2025, or $0.29 per share13.
Operating expenses for the quarter totaled $27.3 million, including approximately $20.2 million in research and development expenses1.
Quarterly earnings beat analyst expectations, with an EPS of -$0.29 versus the consensus estimate of -$0.315.
During the third quarter, Nkarta identified an impairment indicator for its long-lived assets following a sustained decline in its share price, which led to the company's market capitalization dropping below its net asset value1.
Nkarta continues to operate as a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies3.
The company does not currently generate revenue from its principal operations and expects to continue incurring net losses as it advances its R&D pipeline1.
Cash, cash equivalents, restricted cash, and investments as of September 30, 2025, support ongoing operations, though the precise amount is not specified in the available Q3 information1.
Sources:
1. https://www.stocktitan.net/sec-filings/NKTX/10-q-nkarta-inc-quarterly-earnings-report-8e1dfc754248.html
3. https://www.nasdaq.com/press-release/nkarta-reports-third-quarter-2025-financial-results-and-corporate-highlights-2025-11